Co-Artesiane 120 ml

Form: Suspension
Dosage: 120ml
Packaging: Powder for oral suspension 120 ml

Active substance: artemether – lumefantrine

Form: Powder for oral suspension


After reconstitution Co-Artesiane contains a fixed dose combination of

– artemether: 3mg/ml

– lumefantrine: 18 mg/ml


Box containing a bottle for the preparation of 60 ml or 120 ml of drinkable suspension and a graduated measure Co-Artesiane 60 ml: Total content of 180mg arthemether and 1080mg lumefantrine

Co-Artesiane 120 ml: Total content of 360 mg arthemether and 2160mg lumefantrine

After reconstitution, the suspension has a yellow colour and a pleasant coconut taste appreciated by children

Target: children (> 5 kg)

Co-Artesiane is intended for paediatric use, but the product can also be used by adults.

Co‐Artesiane is indicated for the treatment of malaria in children.

CO-ARTESIANE® suspension has been specially designed for children. The dosage depends on the severity of the case and the clinical condition of the patient: usually 4 mg artemether/kg body weight in combination with lumefantrine per day.

This dose will be taken for three consecutive days.

The daily dose is given as a single dose.

Simplified scheme: child’s weight (kg) x 1.5 = the amount (in ml) of Co-Artesiane per dose

Note: To avoid relapse, it is necessary to complete the full three-day course of treatment. If vomiting occurs within 30 minutes of taking the suspension, the full dose should be administered. If vomiting occurs within one hour of taking the suspension, half a dose should be administered.

Consult the scientific information leaflet for the dosage schedule.

Prescription drugs. Please contact your doctor.

Notice of Trademark Infringement

Dear valued partners, customers and Dafra representatives,

It has come to our attention that unauthorized use of our company’s name and logo has been observed in various contexts in the African country Togo ( In order to avoid misunderstandings, ever misleading, we feel it is imperative to address this issue promptly and transparently.

Trademark infringement poses a significant threat not only to our brand integrity but also to the trust and credibility we have worked diligently to establish within our community. Our name and logo represent our values, quality, and commitment to excellence, and any unauthorized use undermines these principles.

We take trademark infringement seriously and are actively taking measures to address any instances of unauthorized use. This includes legal action against parties found to be infringing upon our intellectual property rights.

We urge our customers, partners, African representatives and the general public to remain vigilant and report any suspected instances of trademark infringement directly to us. Your cooperation in this matter is crucial in helping us protect our brand and preserve the integrity of our business.

As always, we remain dedicated to providing high quality medical solutions in the sub-Sahara region of Africa and maintaining the highest standards of integrity and professionalism.

Thank you for your continued support and trust in our company.

Dafra Pharma